BioSpace3d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
mic4d
A Nasal Spray For Depression? FDA Gives Its Approval
This innovative treatment is poised to change the landscape of depression management ... making effective treatments crucial. Spravato is derived from ketamine, a drug that has gained attention ...
Yahoo Finance4d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
3,4,5 "Treatment-resistant depression can be very complicated ... Johnson & Johnson Innovative Medicine. "SPRAVATO ® is now available as a standalone treatment, meaning patients may experience ...
Boing Boing on MSN1d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...